Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus.

Abstract

Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. However, many patients are unaware that melasma is recurrent and requires long-term management. Hydroquinone is effective for controlling relapses and has become the standard of care for melasma in many countries. Nonetheless, it is limited by its side effect profile. Certain patient profiles who have had prior therapy and/or are refractory to treatment may be offered an alternative, that is topical tranexamic acid (TXA) alone or in combination with other modalities. This review provides a summary of current evidence on topical TXA as a treatment for certain case profiles. This paper aims to fill knowledge gaps in terms of currently available options, highlighting the role of topical TXA alone or in combination with other active ingredients (ie, topical TXA 2% with patented delivery technology). J Drugs Dermatol. 2023;22(4): doi:10.36849/JDD.7104 Citation: Desai SR, Chan LC, Handog E, et al. Optimizing melasma management with topical tranexamic acid: An expert consensus. J Drugs Dermatol. 2023;22(4):386-392. doi:10.36849/JDD.7104.

• Authors: Seemal Desai, Lee Chan, Evangeline Handog, Lanny Djojoseputro, Joyce Lim, Ruth Ling, Hao Nguyen, Elias Tam, Jyh Tang, Steven Thng, Hau Tran
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 22 Issue 4 Pg. 386-392 (Apr 01 2023) ISSN: 1545-9616 [Print] United States
• PMID: 37026889 (Publication Type: Review, Journal Article)

Chemical References

• Tranexamic Acid

Topics

• Humans
• Tranexamic Acid
• Consensus
• Melanosis (diagnosis, drug therapy)
• Administration, Topical
• Treatment Outcome